POLE and neoplasm: Further studies may be needed to clarify if indel mutations involving repeat regions in MSI-H tumors contribute highly significantly to tumor responsiveness to anti-PD-1 or anti-PD-L1 immunotherapy and whether missense hypermutations in MSS POLE-mutated tumors may induce sufficient neoantigens for immunotherapy.